BioGaia

Regulatory Filings • Jan 12, 2015

Press Release 12 January 2015

BioGaia signs exclusive agreement in Vietnam

BioGaia has today signed an exclusive agreement with VietPhap International Co Ltd for the rights to sell BioGaia ProTectis Drops in Vietnam. The launch is planned to take place during 2015.

VietPhap International Co Ltd is one of the leading pharmaceutical companies in Vietnam. The company is doing licensing, business development, marketing, sales and distribution of a wide range of products, both over-the-counter and prescription drugs, in many different indication areas. VietPhap markets its products towards health care professionals.

VietPhap will market BioGaia ProTectis Baby Drops, BioGaia's biggest product, and later also launch BioGaia ProTectis Baby Drops with vitamin D. Both products contain the patented and well-documented probiotic strain Lactobacillus reuteri Protectis. Today the drops are sold in 70 countries worldwide.

Vietnam has 90 million inhabitants and a low, but rapidly growing, purchasing power per capita.

"Asia is a market with great potential and I am pleased that BioGaia' products will be available in yet another country here. With the reputable local partner VietPhap we hope for a successful launch of our paediatric portfolio in Vietnam", says Peter Rothschild, President, BioGaia.

For additional information please contact Peter Rothschild, President, telephone: +46 8 555 293 00

Latest press releases from BioGaia

2014-12-11	BioGaia product effective in constipated adults
2014-12-01	BioGaia invests in promising research company
2014-10-24	Infants with colic cry less with BioGaia with BioGaia's drops

BioGaia has published this information in accordance with the Swedish Securities Market Act. The information was issued for publication on 12 January 2015, 09:45 am CET.

BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com